Predictors of metformin failure in gestational diabetes mellitus (GDM)
Abstract
INTRODUCTION AND OBJECTIVE: The role of metformin in gestational diabetes mellitus (GDM) is also increasing. However, almost half of metformin-treated women required additional insulin. Therefore, identifying the characteristics of these women may help define optimal therapeutic strategy.
METHODS: This is a retrospective cohort study done in a District General Hospital, UK. GDM was diagnosed by 75 g OGTT test between 24 and 28 weeks of gestation with fasting levels of ≥6.1 mmol/l and/or 2 h postprandial (PP) level of ≥7.8 mmol/l. Logistic regression and receiver operator curves (ROC) were performed to identify the predictors of metformin failure.
RESULTS: Out of 228 women with GDM included, 46/228 (20.2%) and 151/228 (66.2%) received insulin and metformin as first-line medication respectively. Among the metformin-treated, 13 stopped treatment and were excluded from analysis. Of the included 138 metformin-treated women, 77 (55.8%) required supplementary insulin (metformin failure). Metformin failure group had higher maternal age and fasting glucose level at OGTT, HbA1c at OGTT and earlier gestational age (GA) at medication initiation. Metformin failure was predicted if fasting OGTT level >4.8 mmol/l (69% sensitivity and 62% specificity). If the fasting levels of IADPSG (International Association of Diabetes and Pregnancy Study Groups) criteria and NICE (National Institute of Health and Care Excellence) were used, the positive predictive value was 78% and 77% respectively.…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 228 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.